OVAREX(RM) MAb-B43.13:IFN-γ could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells

Hybridoma

Volumn 16, Issue 1, 1997, Pages 41-45

  Madiyalakan, R ^a   Yang, R ^a   Schultes, B C ^a   Baum, R P ^b   Noujaim, A A ^a  

^a AltaRex Inc   (Canada)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CANCER VACCINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B 43.13; OREGOVOMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; OVARY TUMOR; PRIORITY JOURNAL; ANIMAL; ARTICLE; CELL CULTURE; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MOUSE; NUDE MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; MICE; MICE, NUDE; OVARIAN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0030610294     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1997.16.41     Document Type: Conference Paper

References (21)

1. Noujaim AA, Baum RP, Sykes TR, Madiyalakan R, Sykes CJ, Hertel A, Niesen A, and Hör G: Monoclonal antibody B43.13 for immunoscintigraphy and immunotherapy of ovarian cancer. In: R. Klapdor, ed., Current Tumor Diagnosis: Applications, Clinical Relevance, Trends. W. Zuckschwerdt Verlag, München, 1994, pp. 823-829.
2. Baum RP, Niesen A, Hertel A, Nanci A, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA, and Hör G: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994;73:1121-1125.
3. Wagner U, Reinsberg J, Oehr P, Briele B, Schmidt S, Werner A, Krebs S, and Biersack HJ: Clinical courses of patients with ovarian carcinomas after induction of anti-idiotypic antibodies against a tumor-associated antigen. Tumor Diagnostik & Therapie 1990;11:1-4.
4. Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum RP, Hör G, and Noujaim AA: Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal B43.13. Hybridoma 1995;14:199-203.
5. Krensky AM, Sanches-Madrid F, Robbins E, Nagy J, Springer TA, and Buralcoff SJ: The functional significance, distribution, and structure of LFA-1, LFA-2 and LFA-3. Cell surface antigens associated with LFA-2 and LFA-3 cell surface antigens associated with CTL-target interaction. J Immunol 1983;131:611-616.
6. Isaacs A, and Lindenmann J: Virus interference: The interferon. Proc B Soc Lond (Biol) 1957;147:258-267.
7. De Maeyer E, and De Maeyer-Guignard J: Interferons and Other Regulatory Cytokines. John Wiley, New York, 1988.
8. Kurzrock R: Interferon-gamma In: Cytokine Therapy. Cambridge University, Cambridge, 1992, pp. 131-151.
9. March C, Muller-Holzner E, Gaugg I, Daxenbichler G, and Dapunt O: Modulation of ovarian carcinoma OV 632 antigen by interferons. Oncology 1992;49:53-57.
10. Maraskovsky E, Chen WF, and Shortman K: IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T-cells. J Immunol 1989;143:1210-1214.
11. Tepper RI, Coffman RL, and Leder P: An eosinophil dependent mechanism for the anti-tumor effect of interleukin-4. Science 1992;257:548-551.
12. Heron I, Hokland M, and Berg K: Enhanced expression of β2 microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 1978;75:6215-6219.
13. Fellous M, Kamoun M, Gresser I, and Bono R: Enhanced expression of HLA antigens and β2 microglobulin on the interferontreated human lymphoid cells. Eur J Immunol 1979;9:446-449.
14. Walker EB, Lanier LL, and Warner ML: Concomitant induction of the cell surface expression of la determinants and accessory cell function by a murine macrophage tumor cell line. J Exp Med 1982;155:629-634.
15. Gastl G, Marth C, Leiter E, Gattringer E, Mayer I, Daxenbichler G, Flener R, and Huber C: Effects of human recombinant interferon-alpha-2-argand-gamma on human breast cancer lines: Dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res 1985;45:2957-2961.
16. Marth CH, Zech J, Bock G, Mayer I, and Daxenbichler G: Effects of retinoids and interferon-gamma on cultured breast cancer cells in comparison with tumor necrosis factor alpha. Int J Cancer 1987;40:840-845.
17. Greiner JW, Guadagni F, Noguchi F, Pestka P, Colcher D, Fisher PB, and Schlom J: Recombinant Interferon enhanced monoclonal antibody-targeting of carcinoma lesions in vivo. Science 1987;235:895-898.
18. Greiner JW, HandPH, Noguchi P, Fisher PB, Pestka S, and Schlom J: Enhanced expression of surface tumor-associated antigens on hu-man breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res 1984;44:3208-3214.
19. Marth CH, Fuith L, Bock G, Daxenbichler G, and Dapunt O: Modulation of ovarian carcinoma tumor marker CA125 by Interferon gamma. Cancer Res 1989;49:6538-6542.
20. Aki M, Shimbara N, Takashina M, Akiyama K, and Kagawa S: Interferon-gamma induced different subunit organizations and foundational diversity of proteasomes. J Biochem 1994;115:257-269.
21. Barnd DL, Lan MS, Metzgar RS, and Finn OJ: Major histocompatibilitic complex-unrestricted recognition of tumor-associated antigens by human cytotoxic T-cells. Proc Natl Acad Sci USA 1989;86:7159-7163.